Latest news and press releases about Cadrenal Therapeutics, Inc. Common Stock (CVKD): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation.
Price
| Price | $1.08 |
| Market Cap | $4M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.77 |
| EV / EBITDA | -0.16 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -406.38% |
| Return on Invested Capital | -284.81% |
| Return on Assets | -206.55% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: CLGN · IBIO · ITRM · KLTO · NRSN · NRXS · RLYB
Explore sector: Healthcare · Biotechnology
More sections of CVKD: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks